IBRX
Overvalued by 115.1% based on the discounted cash flow analysis.
Market cap | $5.46 Billion |
---|---|
Enterprise Value | $5.81 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-1.15 |
Beta | 2.59 |
Outstanding Shares | 677,003,411 |
Avg 30 Day Volume | 12,916,505 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -9.36 |
---|---|
PEG | -8.09 |
Price to Sales | - |
Price to Book Ratio | -8.4 |
Enterprise Value to Revenue | 9344.57 |
Enterprise Value to EBIT | -15.76 |
Enterprise Value to Net Income | -10 |
Total Debt to Enterprise | 0.11 |
Debt to Equity | -1.06 |
No data
No data
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms ...